Patents by Inventor Samuel Wadsworth

Samuel Wadsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11299715
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 12, 2022
    Assignee: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Publication number: 20220090131
    Abstract: This application relates to adeno-associated viral vectors encoding a truncated yet functional ATP7B for use in gene therapy for treating Wilson disease (WD). The truncated ATP7B described herein has several advantages over the wild-type ATP7B such as higher efficacy and improved manufacturing yield.
    Type: Application
    Filed: January 3, 2020
    Publication date: March 24, 2022
    Inventors: Christine Livingston, Samuel Wadsworth
  • Publication number: 20220064262
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 3, 2022
    Applicants: Genzyme Corporation, Genzyme Corporation
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Publication number: 20220017922
    Abstract: This invention provides a variety of novel adeno-associated vims (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease type 1a (GSD-Ia). Disclosed herein are a number of recombinant nucleic acid molecules, vectors and recombinant AAV that incorporate a modified G6PC promoter/enhancer sequence. Utilization of the modified G6PC promoter/enhancer sequence results in enhanced AAV yield and quality when expressed from various host cell platforms. Also provided herein are compositions comprising the novel AAV of the invention and methods of treating GSD-Ia using the same.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 20, 2022
    Inventors: Christopher Tipper, Kelly Reed Clark, Samuel Wadsworth
  • Publication number: 20210283272
    Abstract: This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical (compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase ?-subunit (PCCA) or mutations in propionyl-CoA carboxylase ?-subunit (PCCB).
    Type: Application
    Filed: October 1, 2019
    Publication date: September 16, 2021
    Inventors: Matthew Scott Fuller, Samuel Wadsworth, Kelly Reed Clark, Sean Christopher Daugherty, Stewart Craig
  • Patent number: 11084864
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 10, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Patent number: 10920245
    Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 16, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Samuel Wadsworth
  • Publication number: 20210040484
    Abstract: Compositions and methods for treating macular degeneration are disclosed. The methods utilize IL17 inhibitors, such as IL17 receptors, as well as fusion proteins including an IL17 receptor fused with a multimerization domain, and recombinant viral vectors encoding such fusions.
    Type: Application
    Filed: March 31, 2020
    Publication date: February 11, 2021
    Inventors: Samuel WADSWORTH, Abraham SCARIA, Chi-Chao CHAN
  • Patent number: 10640771
    Abstract: Compositions and methods for treating macular degeneration are disclosed. The methods utilize IL17 inhibitors, such as IL17 receptors, as well as fusion proteins including an IL17 receptor fused with a multimerization domain, and recombinant viral vectors encoding such fusions.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: May 5, 2020
    Assignees: GENZYME CORPORATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE
    Inventors: Samuel Wadsworth, Abraham Scaria, Chi-Chao Chan
  • Publication number: 20190345223
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: November 20, 2018
    Publication date: November 14, 2019
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Patent number: 10183983
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: January 22, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Publication number: 20180230490
    Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord.
    Type: Application
    Filed: December 29, 2017
    Publication date: August 16, 2018
    Inventors: Catherine O'RIORDAN, Samuel WADSWORTH
  • Publication number: 20180155417
    Abstract: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Ig like domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
    Type: Application
    Filed: October 17, 2017
    Publication date: June 7, 2018
    Applicant: Genzyme Corporation
    Inventors: Abraham Scaria, Peter Pechan, Samuel Wadsworth
  • Patent number: 9890394
    Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention a transgene product is delivered to a subject's spinal cord by administering a recombinant viral vector containing the transgene to the spinal cord. The viral vector delivers the transgene which expresses the encoded recombinant viral gene product. The viral gene product comprises HIF1-alpha. Also provided are compositions for delivery of a transgene product to a subject's spinal cord.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: February 13, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Samuel Wadsworth
  • Publication number: 20170342127
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 28, 2017
    Publication date: November 30, 2017
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
  • Patent number: 9815892
    Abstract: Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: November 14, 2017
    Assignee: Genzyme Corporation
    Inventors: Abraham Scaria, Peter Pechan, Samuel Wadsworth
  • Patent number: 9637534
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: May 2, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
  • Publication number: 20160068844
    Abstract: Compositions and methods for treating macular degeneration are disclosed. The methods utilize IL17 inhibitors, such as IL17 receptors, as well as fusion proteins including an IL17 receptor fused with a multimerization domain, and recombinant viral vectors encoding such fusions.
    Type: Application
    Filed: April 17, 2014
    Publication date: March 10, 2016
    Inventors: Samuel WADSWORTH, Abraham SCARIA, Chi-Chao CHAN
  • Publication number: 20150353899
    Abstract: The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described.
    Type: Application
    Filed: January 7, 2014
    Publication date: December 10, 2015
    Applicant: Genzyme Corporation
    Inventors: Peter Pechan, Jeffery Ardinger, Abraham Scaria, Samuel Wadsworth
  • Publication number: 20140315804
    Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 23, 2014
    Applicant: GENZYME CORPORATION
    Inventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA